trending Market Intelligence /marketintelligence/en/news-insights/trending/wc_-nx-6iimntv9ucrt8tg2 content esgSubNav
In This List

ASCO conference: PharmaMar drug shrinks tumors in mid-stage trial

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


ASCO conference: PharmaMar drug shrinks tumors in mid-stage trial

PharmaMar SA said its drug lurbinectedin showed antitumor activity in small-cell lung cancer patients, according to data presented at the 2018 American Society of Clinical Oncology meeting.

The Madrid-based company is evaluating the drug as a single agent in different solid tumors, including small-cell lung cancer which returned after one line of prior chemotherapy.

The phase 2 trial began by recruiting 15 patients and later increased to 100 after observing five responses in the first 15 patients.

Of the 61 patients evaluated in the study, 39.3% had a reduction in their tumor size.

The patients responded to the drug for a median of 6.2 months and survived, on average, for 12 months from the start of treatment.

The 2018 American Society of Clinical Oncology meeting is expected to bring together more than 32,000 professionals from all over the world, with more than 2,500 study abstracts to be presented on-site and an additional 3,350 abstracts to be published online.